ASTCT 2022 Fludarabine Shortage Survey Question Title * 1. How would you describe the current impact of the fludarabine shortage? Critical Severe Moderate Low What shortage? Question Title * 2. Has the fludarabine shortage impacted patient care at your institution? Yes No Question Title * 3. If yes, please provide an estimate of the number of patients impacted to date. Question Title * 4. What methods have you implemented to manage the fludarabine shortage? Select all that apply. Dose batching and rounding Extended beyond use dating Patient prioritization/restriction Use of alternative regimens Transplant/CAR-T treatment delay Use of oral fludarabine Obtaining fludarabine from non-US manufacturers Other (please specify) Question Title * 5. Who is primarily responsible for managing the fludarabine shortage at your institution? Clinical pharmacists Pharmacy managers Physicians Multidisciplinary committee, such as P&T committee or other ad-hoc shortage committee Other (please specify) Question Title * 6. If you are prioritizing/restricting fludarabine use to particular patient populations, which are they? CAR-T patients RIC or NMA transplant recipients All allogeneic transplant recipients Clinical trial patients Other (please specify) Question Title * 7. What alternative regimens are you using for CAR-T lymphodepleting chemotherapy (if applicable)? Select all that apply. Bendamustine Cyclophosphamide monotherapy Cyclophosphamide + cladribine Other (please specify) Question Title * 8. What alternative regimens are you using for myeloablative conditioning? Clofarabine + busulfan Cyclophosphamide + busulfan Cyclophosphamide + TBI Etoposide + TBI Other (please specify) Question Title * 9. What alternative regimens are you using for reduced-intensity conditioning? Clofarabine + busulfan Clofarabine + cyclophosphamide + TBI (haplo) Pentostatin + cyclophosphamide + TBI Pentostatin + TBI Pentostatin + cyclophosphamide + busulfan Cladribine + melphalan Cladribine + thiotepa + ATG Cladribine + busulfan Other (please specify) Done